Skip to main content
. 2022 Jan 13;14(2):390. doi: 10.3390/cancers14020390

Figure 1.

Figure 1

KRAS-G12 substitutions in lung (top), pancreatic (middle), and colon (bottom) cancers. Data are based on patient cohorts in TCGA.